ViiV Healthcare, a specialist in HIV treatments, recently released the positive results of its Phase IIb study LATTE1 for investigational, injectable formulations of HIV maintenance therapies.
The study involved the long-acting, investigational, injectable formulations of rilpivirine (from Janssen) and cabotegravir (from ViiV Healthcare). The study results showed that these two injections have comparable results in maintaining HIV viral suppression rates when compared to a three drug oral regimen containing investigational cabotegravir as well as two nucleoside reverse transcriptase inhibitors (NRTIs).
At 32 weeks, the patients with the two drug maintenance therapy involving cabotegravir and rilpivirine doses every four to eight weeks had comparable HIV viral suppression rates with patients who maintained a three-drug oral regimen comprised of cabotegravir and NRTIs.
The most common side effect was pain at the site of the injection. This side effect afflicted 93 percent of the patients involved in the study. Two of the study subjects withdrew from the trial due to injection intolerance. Two additional patients involved met the standard for protocol defined virologic failure criteria.
“ViiV Healthcare is committed to identifying new therapeutic options for physicians and people living with HIV,” John Pottage, ViiV Healthcare’s chief scientific and medical officer, said. “These initial Phase IIb data investigating long-acting cabotegravir and rilpivirine are promising and build on the results we have seen to date. We look forward to seeing further results as we move into Phase III.”
A ViiV Healthcare representative will make a presentation about LATTE 2 at an upcoming scientific conference.
